{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:59:21Z","timestamp":1792241961625,"version":"4.4.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journals.elsevierhealth.com","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.eururo.2014.09.049","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T18:44:28Z","timestamp":1412880268000},"page":"470-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":250,"title":["Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level"],"prefix":"10.1016","volume":"67","author":[{"given":"Theodoros","family":"Karantanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Montironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.09.049_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2014.09.049_bib0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrclinonc.2011.127","article-title":"Bone metastasis in prostate cancer: emerging therapeutic strategies","volume":"8","author":"Sturge","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0015","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cncr.28485","article-title":"No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period","volume":"120","author":"Wu","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.09.049_bib0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0025","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.049_bib0030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2014.09.049_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-13-2665","article-title":"Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary","volume":"20","author":"Kluetz","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0040","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.049_bib0045","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.049_bib0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.eururo.2014.09.049_bib0055","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2014.09.049_bib0060","article-title":"Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study [abstract LBA1]","volume":"32","author":"Beer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0065","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0070","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2013.50.1684","article-title":"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer","volume":"31","author":"Rathkopf","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0075","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/aja.2013.38","article-title":"Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer","volume":"15","author":"Toren","year":"2013","journal-title":"Asian J Androl"},{"key":"10.1016\/j.eururo.2014.09.049_bib0080","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/2159-8290.CD-12-0460","article-title":"Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer","volume":"3","author":"Logothetis","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2014.09.049_bib0085","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0090","doi-asserted-by":"crossref","first-page":"13728","DOI":"10.1073\/pnas.1107898108","article-title":"Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer","volume":"108","author":"Chang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2014.09.049_bib0095","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2014.09.049_bib0100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1200\/JCO.2010.33.7675","article-title":"Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone","volume":"30","author":"Efstathiou","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/JOE-11-0315","article-title":"The diversity of sex steroid action: novel functions of hydroxysteroid (17beta) dehydrogenases as revealed by genetically modified mouse models","volume":"212","author":"Saloniemi","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0110","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/srep01528","article-title":"Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer","volume":"3","author":"Ishizaki","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2014.09.049_bib0115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mce.2008.08.013","article-title":"Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol","volume":"295","author":"Dillard","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0120","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1158\/0008-5472.CAN-12-3128","article-title":"Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1","volume":"73","author":"Lee","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0125","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0130","first-page":"1541","article-title":"Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone","volume":"7","author":"Culig","year":"1993","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0135","first-page":"6","volume":"12","author":"De Wit","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9440(10)63112-4","article-title":"Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance","volume":"16","author":"Holzbeierlein","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0145","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2003.11.102","article-title":"Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B study 9663","volume":"21","author":"Taplin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0150","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.049_bib0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2014.09.049_bib0160","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2014.09.049_bib0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2014.09.049_bib0170","first-page":"2511","article-title":"Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist","volume":"59","author":"Taplin","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0175","first-page":"1541","article-title":"Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone","volume":"7","author":"Culig","year":"1993","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ijc.10495","article-title":"Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer","volume":"100","author":"Steketee","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2014.09.049_bib0185","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.bjc.6690684","article-title":"Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system","volume":"81","author":"Culig","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2014.09.049_bib0190","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1210\/me.2005-0231","article-title":"Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions","volume":"19","author":"Duff","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0195","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/0008-5472.CAN-08-3605","article-title":"Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy","volume":"69","author":"Steinkamp","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0200","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2014.09.049_bib0205","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2014.09.049_bib0210","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/2159-8290.CD-13-0405","article-title":"Resistance emerges to second-generation antiandrogens in prostate cancer","volume":"3","author":"Nelson","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2014.09.049_bib0215","first-page":"6606","article-title":"Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line","volume":"62","author":"Tepper","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0220","doi-asserted-by":"crossref","first-page":"9001","DOI":"10.1158\/0008-5472.CAN-07-1072","article-title":"Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence","volume":"67","author":"Libertini","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0225","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","article-title":"A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth","volume":"69","author":"Guo","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0230","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","article-title":"Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance","volume":"68","author":"Dehm","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Hu","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0240","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/pros.21382","article-title":"A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities","volume":"71","author":"Hu","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2014.09.049_bib0245","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2014.09.049_bib0250","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1172\/JCI41824","article-title":"Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant","volume":"120","author":"Sun","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2014.09.049_bib0255","doi-asserted-by":"crossref","first-page":"e19059","DOI":"10.1371\/journal.pone.0019059","article-title":"Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival","volume":"6","author":"H\u00f6rnberg","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.eururo.2014.09.049_bib0260","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0265","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0275","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1535-7163.MCT-13-0027","article-title":"NF-\u03baB2\/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants","volume":"12","author":"Nadiminty","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2014.09.049_bib0280","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","article-title":"Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration resistant prostate cancer","volume":"20","author":"Liu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0285","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.049_bib0290","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/0008-5472.CAN_10-3398","article-title":"Small molecule inhibitors targeting the \u201cAchilles\u2019 heel\u201d of androgen receptor activity","volume":"71","author":"Sadar","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0485","unstructured":"Efstathiou E, Titus M, Wen AS, SanMiguel A, Hoang A, De Haas-Amatsaleh A, et al. The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC). Presented at: European Cancer Congress 2013; 27 September\u20131 October 2013; Amsterdam, The Netherlands. Abstract 2854."},{"key":"10.1016\/j.eururo.2014.09.049_bib0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2006.08.021","article-title":"Regulation of androgen receptor activity by tyrosine phosphorylation","volume":"10","author":"Guo","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2014.09.049_bib0300","doi-asserted-by":"crossref","first-page":"38087","DOI":"10.1074\/jbc.M203313200","article-title":"Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells","volume":"277","author":"Ueda","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.eururo.2014.09.049_bib0305","doi-asserted-by":"crossref","first-page":"7959","DOI":"10.1158\/0008-5472.CAN-04-3541","article-title":"Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression","volume":"65","author":"Agoulnik","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0310","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/1535-7163.MCT-08-0823","article-title":"Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2","volume":"8","author":"Feng","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2014.09.049_bib0315","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.1158\/0008-5472.CAN-06-1023","article-title":"Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer","volume":"66","author":"Agoulnik","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0320","first-page":"5474","article-title":"Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor","volume":"54","author":"Culig","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0325","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ccr.2004.09.031","article-title":"HER2\/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability","volume":"6","author":"Mellinghoff","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2014.09.049_bib0330","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1158\/1078-0432.CCR-11-1548","article-title":"Dual EGFR\/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3","volume":"17","author":"Chen","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0335","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2014.09.049_bib0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2014.09.049_bib0345","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1158\/0008-5472.CAN-13-2485","article-title":"P300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis","volume":"74","author":"Zhong","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0350","first-page":"5632","article-title":"p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6","volume":"62","author":"Debes","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0355","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1464-410X.2007.07261.x","article-title":"Efficacy of low-dose dexamethasone in castration-refractory prostate cancer","volume":"101","author":"Venkitaraman","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.09.049_bib0360","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/sj.onc.1209991","article-title":"Tumor suppressor activity of glucocorticoid receptor in the prostate","volume":"26","author":"Yemelyanov","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.eururo.2014.09.049_bib0365","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-12-2350","article-title":"FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells","volume":"73","author":"Sahu","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0370","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2014.09.049_bib0375","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1677\/jme.0.0050117","article-title":"Association of glucocorticoid receptors with prostate nuclear sites for androgen receptors and with androgen response elements","volume":"5","author":"Davies","year":"1990","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0380","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","article-title":"Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1","volume":"20","author":"Cai","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2014.09.049_bib0385","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","article-title":"Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth","volume":"19","author":"Mulholland","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2014.09.049_bib0390","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1093\/emboj\/cdf406","article-title":"Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase","volume":"21","author":"Lin","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.eururo.2014.09.049_bib0395","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1464-410X.2012.11456.x","article-title":"Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer","volume":"110","author":"Nakabayashi","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.09.049_bib0400","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ccr.2011.12.024","article-title":"Inhibition of PI3K\/mTOR leads to adaptive resistance in matrix-attached cancer cells","volume":"21","author":"Muranen","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2014.09.049_bib0405","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2014.09.049_bib0410","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/en.2010-0436","article-title":"Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer","volume":"151","author":"Bohrer","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.eururo.2014.09.049_bib0415","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.eururo.2014.09.049_bib0420","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2353\/ajpath.2008.071054","article-title":"Stat3 promotes metastatic progression of prostate cancer","volume":"172","author":"Abdulghani","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0425","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/0008-5472.CAN-13-0594","article-title":"Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling","volume":"74","author":"Schroeder","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0430","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/pros.22741","article-title":"Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells","volume":"74","author":"Liu","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2014.09.049_bib0435","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0065-230X(04)91002-0","article-title":"Prostate cancer and the met hepatocyte growth factor receptor","volume":"91","author":"Knudsen","year":"2004","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0440","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1006\/bbrc.1996.1710","article-title":"Hepatocyte growth factor is a paracrine regulator of rat prostate epithelial growth","volume":"228","author":"Kasai","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.eururo.2014.09.049_bib0445","first-page":"386","article-title":"Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma","volume":"147","author":"Humphrey","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0450","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ucl.2012.07.008","article-title":"Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor","volume":"39","author":"Loriot","year":"2012","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2014.09.049_bib0455","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/0008-5472.CAN-06-3552","article-title":"The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of PCa progression","volume":"67","author":"Verras","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.049_bib0460","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3892\/ijo.2013.2020","article-title":"From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells","volume":"43","author":"Liu","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0465","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.049_bib0470","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005070","article-title":"Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer","volume":"7","author":"Li","year":"2014","journal-title":"Sci Signal"},{"key":"10.1016\/j.eururo.2014.09.049_bib0475","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.4161\/cc.9.15.12515","article-title":"New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer","volume":"9","author":"Stenman","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.eururo.2014.09.049_bib0480","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6601127","article-title":"Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer","volume":"89","author":"Edwards","year":"2003","journal-title":"Br J Cancer"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814010008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814010008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T19:05:15Z","timestamp":1717441515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283814010008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0302283814010008"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.09.049","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.09.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}